A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Glaxo Wellcome
- Study ID
- NCT00002084
- Status
- Completed
Conditions
- HIV Infections
- Herpes Simplex
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Valacyclovir hydrochloride — DRUG
- Acyclovir — DRUG
Study Details
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.
Key Dates
- Status verified
- Apr 1996
Study Design
- Primary purpose
- TREATMENT
Locations (46)
Find similar trials in Mobile, AL
By condition
By specialty
Related Studies
- SCOPE: Observational Study of the Consequences of the Protease Inhibitor EraRecruiting · University of California, San Francisco · San Francisco, California
- Imaging Immune Activation in HIV by PET-MRPHASE2 · Recruiting · CellSight Technologies, Inc. · San Francisco, California
- Skeletal Muscle Energetics and Fatiguability in Older IndividualsRecruiting · Johns Hopkins University · Baltimore, Maryland
- HIV Prevention Among At-risk Latinos in the HeartlandEnrolling By Invitation · Medical College of Wisconsin · Indianapolis, Indiana